View Older Stories View More Recent Stories

Jan 7, 2020 07:00AM Summit Therapeutics Launches Online Resource for Patients with C. difficile Infection
Dec 17, 2019 07:00AM Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019
Dec 16, 2019 09:15AM Notice of Q3 Results
Nov 6, 2019 07:00AM Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress
Nov 4, 2019 07:00AM Summit Therapeutics Recognises C. difficile Awareness Month
Oct 16, 2019 07:00AM Summit Therapeutics to Present at the 2019 BIO Investor Forum
Oct 11, 2019 07:00AM Half-year report
Oct 10, 2019 09:30AM Notice of Results
Oct 7, 2019 07:00AM Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection
Oct 3, 2019 07:00AM Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care
Sep 25, 2019 07:00AM Summit Therapeutics to Host R&D Day 7 October 2019
Sep 24, 2019 07:00AM Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019
Sep 18, 2019 02:00AM Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes
Sep 5, 2019 07:00AM Summit Presented In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotics at ASM/ESCMID Conference
Sep 4, 2019 07:00AM Summit Therapeutics to Participate in Upcoming Investor Conferences
Aug 1, 2019 07:00AM Summit Therapeutics to Present at the Canaccord Genuity Growth Conference
Jul 17, 2019 07:00AM Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress
Jul 9, 2019 07:00AM Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia
Jun 20, 2019 07:00AM Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019
Jun 18, 2019 07:00AM Increased BARDA Award and Option Exercise
Jun 12, 2019 07:00AM Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019
Jun 5, 2019 09:00AM Notice of First Quarter Results
Apr 14, 2019 07:42AM Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
Apr 3, 2019 07:00AM Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae
Apr 2, 2019 07:00AM Summit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences Conference
Mar 29, 2019 01:45PM Award of Share Options
Mar 27, 2019 07:00AM Final Results
Mar 25, 2019 07:00AM Notice of Results
Mar 18, 2019 07:00AM Summit Therapeutics to Present at Upcoming Conferences
Mar 14, 2019 07:00AM Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference
Feb 25, 2019 02:00AM Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data
Feb 13, 2019 02:00AM Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection
Feb 8, 2019 02:00AM Summit Therapeutics to Present at the BIO CEO & Investor Conference
Jan 10, 2019 02:00AM Completion of $25 million subscription
Dec 16, 2018 09:05PM Proposed Subscription to Raise $25m and Notice of General Meeting
Dec 16, 2018 09:00PM Summit Therapeutics Announces Departure of Chief Financial Officer
Dec 11, 2018 02:00AM 3rd Quarter Results
Dec 6, 2018 02:00AM Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 on 11 December 2018
Nov 12, 2018 02:00AM Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week
Nov 7, 2018 02:00AM Summit Therapeutics to Participate in Jefferies 2018 London Healthcare Conference
Nov 1, 2018 03:00AM Summit Recognises C. difficile Awareness Month
Oct 10, 2018 03:00AM Summit Therapeutics to Participate in Upcoming Investor Events
Oct 7, 2018 10:00PM Surrender of Share Options
Oct 3, 2018 03:00AM Summit Highlights Phase 3-Ready Precision Antibiotic Ridinilazole at IDWeek 2018
Sep 26, 2018 03:00AM Summit to Highlight Potential of Precision Antibiotic Ridinilazole to Treat C. difficile Infection and Reduce Recurrent Disease at ID Week 2018
Sep 20, 2018 03:00AM Summit Reports Financial Results for the Second Quarter Ended 31 July 2018 and Operational Progress
Sep 14, 2018 03:00AM Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2018 on 20 September 2018
Sep 14, 2018 03:00AM Summit Therapeutics to Participate in Upcoming Investor Conferences
Sep 6, 2018 03:00AM Summit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets
Sep 5, 2018 03:00AM Summit Nominates New Mechanism Antibiotic SMT-571 as its Lead Clinical Candidate for the Treatment of Gonorrhoea
View More Recent Stories View Older Stories